Loomis, Sayles & Company
SAGE icon

Loomis, Sayles & Company’s Sage Therapeutics SAGE Stock Holding History

Loomis, Sayles & Company’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-66
Closed -$2K – 1038
2022
Q1 		$2K Buy
+66
New +$2.48K ﹤0.01% 967
2021
Q4 		– Sell
-166
Closed -$7K – 882
2021
Q3 		$7K Buy
+166
New +$7.61K ﹤0.01% 877
2021
Q1 		– Sell
-189
Closed -$16K – 883
2020
Q4 		$16K Buy
+189
New +$13.9K ﹤0.01% 645

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Loomis, Sayles & Company's SAGE Position: Q2 2022 in Review

Loomis, Sayles & Company sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 66 shares — an estimated $2K sold.

Loomis, Sayles & Company first reported a position in SAGE in Q4 2020 and held it in 3 quarters. The position peaked at $16K in Q4 2020. 210 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Loomis, Sayles & Company reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 66 Sage Therapeutics shares in Q2 2022, an estimated $2K.
  • Loomis, Sayles & Company first reported a position in Sage Therapeutics in Q4 2020 and held it in 3 quarters.
  • Loomis, Sayles & Company's Sage Therapeutics position peaked at $16K in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Loomis, Sayles & Company's 13F filing for Q2 2022, filed 5 Aug 2022.